Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome

References

• Glassock RJ, Fervenza FC, Hebert L, et al. Nephrotic syndrome redux. Nephrol Dial Transplant. 2015;30(1):12–17.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41–52.
   PubMed Web of Science ®Google Scholar
• Joven J, Villabona C, Vilella E, et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med. 1990;323(9):579–584.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat Rev Nephrol. 2016;12(1):37–47.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Zaritsky JJ, Fornoni A, et al. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14(1):57–70.
   PubMed Web of Science ®Google Scholar
• Vega GL, Toto RD, Grundy SM. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int. 1995;47(2):579–586.
   PubMed Web of Science ®Google Scholar
• Chung JJ, Huber TB, Gödel M, et al. Albumin-associated free fatty acids induce macropinocytosis in podocytes. J Clin Invest. 2015;125(6):2307–2316.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. J Ren Nutr. 2010;20(5):S35–S43.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clin Exp Nephrol. 2014;18(2):265–268.
   PubMed Web of Science ®Google Scholar
• Ordonez JD, Hiatt RA, Killebrew EJ, et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993;44(3):638–642.
   PubMed Web of Science ®Google Scholar
• Liu S, Vaziri ND. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol Dial Transplant. 2014;29(3):538–543.
   PubMed Web of Science ®Google Scholar
• Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004;101(18):7100–7105.
   PubMed Web of Science ®Google Scholar
• Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006;116(11):2995–3005.
   PubMed Web of Science ®Google Scholar
• Li J, Tumanut C, Gavigan JA, et al. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J. 2007;406(2):203–207.
   PubMedGoogle Scholar
• Schmit D, Fliser D, Speer T. Proprotein convertase subtilisin/kexin type 9 in kidney disease. Nephrol Dial Transplant. 2019;34(8):1266–1271.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Alborn WE, Cao G, Careskey HE, et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem. 2007;53(10):1814–1819.
   PubMed Web of Science ®Google Scholar
• Chan DC, Lambert G, Barrett PH, et al. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism? Clin Chem. 2009;55(11):2049–2052.
   PubMed Web of Science ®Google Scholar
• Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Supplement):S172–S177.
   PubMedGoogle Scholar
• Haas ME, Levenson AE, Sun X, et al. The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation. 2016;134(1):61–72.
   PubMed Web of Science ®Google Scholar
• Jin K, Park BS, Kim YW, et al. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 2014;63(4):584–589.
   PubMed Web of Science ®Google Scholar
• Fan D, Yancey PG, Qiu S, et al. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry. 2008;47(6):1631–1639.
   PubMed Web of Science ®Google Scholar
• Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res. 2010;51(6):1486–1495.
   PubMed Web of Science ®Google Scholar
• Jeong HJ, Lee HS, Kim KS, et al. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res. 2008;49(2):399–409.
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Liang KH. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome. Circulation. 2004;110(4):419–425.
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Liang K. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int. 2002;61(5):1769–1775.
   PubMed Web of Science ®Google Scholar
• Muso E, Mune M, Hirano T, et al. Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clin Exp Nephrol. 2015;19(3):379–386.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, O'donnell MP, Cleary MP, et al. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988;33(3):667–672.
   PubMed Web of Science ®Google Scholar
• Shibata S, Nagase M, Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol. 2006;17(3):754–764.
   PubMed Web of Science ®Google Scholar
• Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008;49(2):394–398.
   PubMed Web of Science ®Google Scholar
• Morino J, Hirai K, Kaneko S, et al. Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody: a case report. Ren Fail. 2020;42(1):173–178.
   PubMed Web of Science ®Google Scholar